Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
KYORIN Holdings, Inc. (4569.T)
Tokyo, JP
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.28% | -11.46% | -17.39% | -17.89% | -2.70% | -12.03% | -7.32% | -21.56% | -19.05% | -33.40% | -48.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.9% Q1'26: -17.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-62.1% Q1'26: -110.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.8% Q1'26: -3.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%—
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×— Q1'26: -7.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
113.12B
est: 112.65B (+0.4%)
|
119.48B
est: 119.40B (+0.1%)
|
115.37B
est: 115.60B (-0.2%)
|
110.64B
est: 111.20B (-0.5%)
|
113.62B
est: 112.60B (+0.9%)
|
109.98B
est: 113.10B (-2.8%)
|
102.90B
est: 105.80B (-2.7%)
|
105.53B
est: 108.30B (-2.6%)
|
113.27B
est: 110.70B (+2.3%)
|
119.53B
est: 120.10B (-0.5%)
|
130.09B
est: 124.00B (+4.9%)
|
126.10B
126.10B – 126.10B
+1.7% YoY
|
125.58B
125.58B – 125.58B
-0.4% YoY
|
127.92B
127.92B – 127.92B
+1.9% YoY
|
128.13B
128.13B – 128.13B
+0.2% YoY
|
128.85B
128.85B – 128.85B
+0.6% YoY
|
| EBITDA |
17.79B
est: 11.82B (+50.5%)
|
23.37B
est: 12.53B (+86.5%)
|
14.03B
est: 12.13B (+15.7%)
|
12.45B
est: 11.67B (+6.7%)
|
11.90B
est: 11.81B (+0.7%)
|
10.71B
est: 11.87B (-9.7%)
|
9.34B
est: 11.10B (-15.9%)
|
8.72B
est: 11.36B (-23.3%)
|
8.96B
est: 11.61B (-22.8%)
|
10.52B
est: 11.34B (-7.3%)
|
17.15B
est: 11.71B (+46.4%)
|
11.91B
11.91B – 11.91B
+1.7% YoY
|
11.86B
11.86B – 11.86B
-0.4% YoY
|
12.08B
12.08B – 12.08B
+1.9% YoY
|
12.10B
12.10B – 12.10B
+0.2% YoY
|
12.17B
12.17B – 12.17B
+0.6% YoY
|
| EBIT |
14.74B
est: 7.88B (+87.1%)
|
19.64B
est: 8.35B (+135.2%)
|
10.41B
est: 8.08B (+28.8%)
|
8.81B
est: 7.77B (+13.3%)
|
8.96B
est: 7.87B (+13.8%)
|
7.49B
est: 7.91B (-5.3%)
|
5.78B
est: 7.40B (-21.9%)
|
5.00B
est: 7.57B (-33.9%)
|
5.12B
est: 7.74B (-33.8%)
|
6.23B
est: 7.14B (-12.8%)
|
12.55B
est: 7.37B (+70.2%)
|
7.50B
7.50B – 7.50B
+1.7% YoY
|
7.47B
7.47B – 7.47B
-0.4% YoY
|
7.61B
7.61B – 7.61B
+1.9% YoY
|
7.62B
7.62B – 7.62B
+0.2% YoY
|
7.66B
7.66B – 7.66B
+0.6% YoY
|
| Net Income |
12.06B
est: 9.02B (+33.7%)
|
13.64B
est: 10.23B (+33.4%)
|
7.31B
est: 5.60B (+30.5%)
|
6.57B
est: 6.63B (-0.8%)
|
6.87B
est: 6.73B (+2.1%)
|
6.15B
est: 6.62B (-7.1%)
|
6.13B
est: 5.20B (+17.8%)
|
3.93B
est: 4.44B (-11.5%)
|
4.72B
est: 4.63B (+2.0%)
|
5.48B
est: 5.38B (+1.8%)
|
9.09B
est: 5.09B (+78.5%)
|
4.84B
4.84B – 4.84B
-5.0% YoY
|
4.46B
4.46B – 4.46B
-7.8% YoY
|
4.94B
4.94B – 4.94B
+10.8% YoY
|
5.00B
5.00B – 5.00B
+1.2% YoY
|
5.11B
5.11B – 5.11B
+2.3% YoY
|
| SGA |
38.27B
est: 37.47B (+2.1%)
|
39.47B
est: 39.71B (-0.6%)
|
40.54B
est: 38.45B (+5.4%)
|
38.51B
est: 36.99B (+4.1%)
|
37.65B
est: 37.45B (+0.5%)
|
38.54B
est: 37.62B (+2.5%)
|
36.14B
est: 35.19B (+2.7%)
|
35.54B
est: 36.02B (-1.3%)
|
34.14B
est: 36.82B (-7.3%)
|
37.38B
est: 38.00B (-1.7%)
|
36.45B
est: 39.24B (-7.1%)
|
39.90B
39.90B – 39.90B
+1.7% YoY
|
39.74B
39.74B – 39.74B
-0.4% YoY
|
40.48B
40.48B – 40.48B
+1.9% YoY
|
40.55B
40.55B – 40.55B
+0.2% YoY
|
40.77B
40.77B – 40.77B
+0.6% YoY
|
| EPS |
161.63
est: 157.03 (+2.9%)
|
184.27
est: 178.01 (+3.5%)
|
99.44
est: 97.43 (+2.1%)
|
89.26
est: 115.38 (-22.6%)
|
104.68
est: 117.10 (-10.6%)
|
107.34
est: 115.20 (-6.8%)
|
106.99
est: 90.60 (+18.1%)
|
68.62
est: 77.30 (-11.2%)
|
82.42
est: 80.60 (+2.3%)
|
95.40
est: 93.60 (+1.9%)
|
158.16
est: 88.60 (+78.5%)
|
84.20
84.20 – 84.20
-5.0% YoY
|
77.60
77.60 – 77.60
-7.8% YoY
|
86.00
86.00 – 86.00
+10.8% YoY
|
87.00
87.00 – 87.00
+1.2% YoY
|
89.00
89.00 – 89.00
+2.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.06% | 236.2K | 0.58% |
| 2 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.04% | 135.7K | 0.31% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.04% | 1.90M | 0.42% |
| 4 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 211.0K | 0.24% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 271.8K | 0.40% |
| 6 | iShares MSCI Japan Small-Cap ETF SCJ | 0.03% | 70.3K | 0.50% |
| 7 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.02% | 108.8K | 0.58% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 38.7K | 0.30% |
| 9 | BMO MSCI EAFE Small-Mid Cap Index ETF ZESM.TO | 0.01% | 32.8K | 0.40% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 599.5K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Junichi Ishiyama | Managing Executive Officer, CSO & Head of Drug Discovery Div. | — | — |
| Katsuhiro Hamada | Executive Officer & GM of Reliability Assurance Headquarters | — | — |
| Kenichi Nakamura | Corporate Officer & President of KYORIN Pharmaceutical Group Facilities Co., Ltd. | — | male |
| Kimiya Masada | Corporate Officer & Director of Product Strategy | — | — |
| Kiyoo Uehara | Managing Executive Officer, CHRO & General Affairs Manager | — | — |
| Makoto Yanai | Executive Officer & Deputy GM of Business Development Division | — | — |
| Michiro Onota | Exe. Director, Mng. Corp. Off., CMO, Chairman of KYORIN Pharmaceutical Grp. Facilities Co., Ltd | — | male |
| Noriaki Tamura | Managing Executive Officer, Chief Commercial Officer & GM of Pharmaceutical Sales Division | — | — |
| Takaaki Kaji | Senior Managing Executive Officer & Chief Business Development Officer | — | — |
| Yasuji Kurose | CFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director | — | male |
| Yutaka Ogihara | President, Chief Executive Officer & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4569.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
